The effective rate of anti-PD-1/PD-L1, a novel therapy for non-small cell lung cancer (NSCLC), administered alone is approximately 20-30%, while the effective rate of conventional chemotherapy combined with immunotherapy is only 50% 7. Here, PDCD1 is linked to non-small cell lung carcinoma.